Cooley U: Evaluating the Opportunity for a Reverse Merger

Mar 6 2018

It can be tricky to communicate the full potential of your discoveries without spilling the secret sauce. Join us for a special presentation from Kara Bortone on learning the tricks of the trade in preparing a non-confidential deck and executive summary. She will share practical tips on becoming more effective in communicating your story to Angel investors and VCs, increasing your chances of successful fundraising.

After Kara’s presentation, join us for a panel discussion where investors and an entrepreneur will share their experiences on best practices and pet peeves when it comes to pitching your science.

Kara Bortone | Head, JLABS San Diego, Johnson & Johnson Innovation, JLABS read bio»
Bryan Walker | Chief Executive Officer, Animantis read bio»

11:00AM | Registration Opens and Networking
11:30AM | Presentation
11:50AM | Panel and Q&A
12:30PM | Lunch and Networking
1:30PM | Program Close

Who should attend:
This event is ideal for inventors in academic centers and hospitals, and early stage healthcare start-ups in the pharma, medical device, consumer health and digital innovation areas.

$25 | General Public
$15 | Student
$35 | At the Door

Includes presentation, Q&A, and lunch.

JLABS in San Diego
3210 Merryfield Row
San Diego, CA

Speaker Biographies:
Kara Bortone | Head JLABS San Diego, Johnson & Johnson Innovation, JLABS
Kara is the Head of JLABS San Diego. In this role, Kara is responsible for external engagement, innovation sourcing, company onboarding, portfolio management, operational excellence, educational programming and P&L. She catalyzes and supports the translation of science and technology into valuable solutions for patients and consumers across the pharmaceutical, medical device and consumer healthcare sectors. 

Bryan Walker | Chief Executive Officer, Animantis 
Bryan the founder and CEO of Animantis, an early stage company that has developed an AI-based drug discovery platform focused on modeling complex cellular behaviors and interactions to better predict drug efficacy. As CEO, Bryan has been responsible for developing the overall strategy for the company, securing financing, and engaging pharmaceutical and academic partners leveraging Animantis’ proprietary platform. Prior to founding Animantis in 2014, Bryan was a researcher at Yale University. During his time as a researcher at Yale, Bryan developed modular engineered tissue models to more effectively characterize primary innate immune cell function in vitro. Bryan graduated from Yale University with a B.S. in Biomedical Engineering in 2013.